英菲格拉替尼现在在上海能够买到吗？

Cholangiocarcinoma is a malignant tumor that occurs from the left and right bile ducts to the lower end of the common bile duct. It mostly occurs in men aged 50 to 70 years old, and most of them are hilar cholangiocarcinoma (HCCA). At present, surgical treatment is the curative method for cholangiocarcinoma and is also the preferred treatment option. The 5-year survival rate after surgery is 18% to 42%. For those who cannot be treated with surgical resection, palliative treatment is feasible. It is an anti-tumor drug that inhibits tumor growth in cholangiocarcinoma. Demonstrated antitumor activity in mouse and rat transplanted human xenograft tumor models with activating FGFR2 or FGFR3 alterations, such as FGFR2-TTC28 or FGFR2-TRA2B fusions. In clinical trials, infitinib was used to treat patients with cholangiocarcinoma, and the overall effective rate was 23%. Some patients achieved complete responses, with response durations as long as 5.5 months, ranging from 0.03 to 28.3 months.

So, can Infigratinib be purchased in Shanghai now?

Regarding this issue, the editor can only unfortunately tell you that Infigratinib is not yet available in China. In other words, no hospital or pharmacy in Shanghai sells this drug. Many patients have no way to seek medicine and will choose to go overseas. That is the only life-saving way to purchase medicine. But patients who have been there know that this overseas drug purchasing journey is not easy. Language barriers, authenticity of drugs, and round-trip travel expenses are all heavy burdens on patients' shoulders. At this time, patients may wish to let the domestic overseas medical service medical institution Medical Companion Travel help you purchase Infigratinib. This reliable organization, Medical Companion Travel, can not only guarantee the authenticity of the drug, but also save you the trouble of traveling back and forth overseas. It is very convenient and safe. If you have more questions about Infigratinib, please contact Medical Companion Travel, and Medical Companion Travel will serve you wholeheartedly.

Original source: [1] oazzami B, Majidzadeh AK, Moghadam AD, et al. Cholangiocarcinoma: State of the art［J］． J Gastrointestl Canc, 2020, 51:774-781．

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.